Currently Viewing:
COA Community Oncology Conference 2019
Currently Reading
COA Close to Filing OCM 2.0 for Federal Review
April 05, 2019
Katie Goodman: Bring Clinical Trials to the Community Setting to Meet Patients Where They Are
April 05, 2019
Dr Howard Burris on Efforts Needed to Ensure Access to NGS Testing
April 05, 2019
Dr Lee Schwartzberg Explains the Promise of Liquid Biopsies in Cancer
April 06, 2019
Dr C.K. Wang Discusses How Real-World Data Can Benefit Payers
April 06, 2019
Pharma Discusses How to Reframe Value in Era of Precision Medicine, Combinations
April 06, 2019
Step Therapy in Medicare Advantage Hurts Patients, Providers, Says Schwartzberg
April 06, 2019
Dr Basit Chaudhry Outlines Findings From OCM PP3
April 07, 2019
Dr Jeffrey Scott on Pharma's Role in Understanding the Value of Novel, Expensive Therapies
April 07, 2019
Dr Jeff Patton on OCM PP3 Results, Challenges With the Model
April 09, 2019
Dr Sonia T. Oskouei Discusses Uptake, Cost Savings With Filgrastim Biosimilar Xarzio
April 11, 2019
Katie Goodman on FDA's Efforts to Expand Patient Inclusion Criteria for Clinical Trials
April 11, 2019
Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer
April 12, 2019
Dr C.K. Wang on How Real-World Data Provide a More Comprehensive Picture of Drug Efficacy
April 14, 2019
Dr Basit Chaudhry on Challenges With Improving Performance Under OCM
April 17, 2019
Dr Jeff Patton Explains How Physician Shortage, Burnout Are Impacting Community Oncologists
April 22, 2019
Dr Lee Schwartzberg on Genetic Testing for All Patients Diagnosed With Breast Cancer
April 23, 2019
Dr Sonia Oskouei Explains the Importance of Education Around Biosimilars
April 24, 2019
Katie Goodman Discusses Clinical Trial Participation Criteria's Impact on Trial Participation
April 25, 2019
Dr C.K. Wang: How COTA's Real-World Data Platform Helps Oncologists Make Informed Decisions
April 27, 2019
What Dr Howard Burris Will Focus on as ASCO President
April 28, 2019
Dr Basit Chaudhry: Evaluating the Adequacy of Novel Therapy Adjustment Under OCM
April 29, 2019
Dr Lee Schwartzberg Outlines Challenges With Accessing Multigene Testing in the Community Setting
May 07, 2019
Dr Jeff Patton Discusses CMS' Proposal to Ease Protections on 6 Drug Classes in Part D
May 08, 2019

COA Close to Filing OCM 2.0 for Federal Review

Mary Caffrey
The first day of the 2019 Community Oncology Conference, the major annual meeting of the Community Oncology Alliance (COA), featured an update on its effort to find alternatives to CMS' Oncology Care Model.
After a year in development, the Community Oncology Alliance (COA) will file its alternative to CMS’ Oncology Care Model (OCM) later this month with the Physician-Focused Payment Model Technical Advisory Committee (PTAC), a federal agency that reviews models for possible use by Medicare.

Bo Gamble, COA’s director of strategic practice initiatives, announced Thursday that the plan known as “OCM 2.0” was near completion during a panel discussion on the first day of the 2019 Community Oncology Conference, taking place in Orlando, Florida. Gamble appeared with Basit Chaudhry, MD, PhD, founder and Chief Executive Officer of Tuple Health; Kavita Patel, MD, MS, a former Obama administration policy official also with Tuple Health; and Bruce Gould, MD, medical director of Northwest Georgia Oncology Centers, chair of COA’s committee on oncology payment reform.

Gamble, Patel, and Gould previously reported on OCM 2.0 last fall during COA’s Payer Exchange Summit, describing it as a template that could be used by Medicare, commercial payers, and even self-insured employers, by addressing many of the frustrations that community oncology practices see with the current incarnation of OCM. These include issues with patient attribution, too many reporting burdens, methodological flaws in the rating of geography and quality measures, and a reimbursement scheme that has not kept pace with the soaring cost of oncology therapies. Most of all, as COA expressed a year ago, a lack of transparency makes it difficult to participants to understand their results.

Thursday’s session, “From OCM 1.0 to 2.0: Two Paths to Payment Reform,” offered an additional update on the complexities of CMS’ signature 5-year alternative payment model (APM), which covers 176 practices and is scheduled to run through June 2021. So far, no plan for an OCM extension or successor has been announced, and Gamble said after the session that practices need information on what will come next.

Chaudhry explained that OCM has reached a crossroads.  Early on in the model, practices often focused on implementing administrative requirements.  As a result, more substantive clinical transformation efforts frequently started later.  Results from performance period 3, which came out a few weeks ago, did not show progressive improvement overall. The share of practices that received a performance-based payment in performance period 3 was the same as the share of practices in performance period 2.  The percent of practices achieving shared savings didn’t increase.

With OCM practices facing a deadline to decide if they will take on 2-sided risk, he said, “both of these trends are quite concerning.”

Gamble and Gould said that there are many things about the OCM that have improved cancer care, but the way the model handles drug pricing means that practices that are doing everything right can still miss out on shared savings.

“I’m a big believer in personal responsibility,” Gould said. Oncology practices should be good stewards of healthcare dollars; they must provide team-based care that helps patients navigate their way through cancer treatment, including “closing the loop” after a consultation.

But, he said, the OCM uses pricing models that were developed with claims data from 2012 to 2015, before the explosion of immuno-oncology drugs. Not only do newer drugs cost more per month, but patients take today’s targeted therapies for longer periods of time. Even with OCM changes like the novel therapy adjustment and the trend factor, Gould said, “[the] pricing model is not relevant with what we do today.”



Related Articles

COA's OCM 2.0: Moving Toward a Universal Payment Model
Dr Sibel Blau Explains What the Results of OCM Have Shown
Common Factors Among Successful Practices in the OCM
COA Releases 2018 Year in Review
COA Submits Comments on CMS' Proposed CAR T-Cell Coverage Decision
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up